RECRUITING

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Talk to us

Conditions

Alzheimer's DiseaseSynapsesCognitionNeuroprotectionNeuronsmGluR5

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease

Official Title

A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease

Quick Facts

Study Start:2023-03-28
Study Completion:2025-07-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05804383

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Carol Gunnoud
CONTACT
203-764-8100
carol.gunnoud@yale.edu

Principal Investigator

Adam Mecca, MD, PhD
STUDY_DIRECTOR
Yale University
Stephanie Post, MD
PRINCIPAL_INVESTIGATOR
Spaulding Clinical Research (Stage 1)
Adam Mecca, MD, PhD
PRINCIPAL_INVESTIGATOR
Yale University (Stage 2)

Study Locations (Sites)

Yale University
New Haven, Connecticut, 06511
United States
Spaulding Clinical Research
West Bend, Wisconsin, 53095
United States

Collaborators and Investigators

Sponsor: Allyx Therapeutics

  • Adam Mecca, MD, PhD, STUDY_DIRECTOR, Yale University
  • Stephanie Post, MD, PRINCIPAL_INVESTIGATOR, Spaulding Clinical Research (Stage 1)
  • Adam Mecca, MD, PhD, PRINCIPAL_INVESTIGATOR, Yale University (Stage 2)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-28
Study Completion Date2025-07-15

Study Record Updates

Study Start Date2023-03-28
Study Completion Date2025-07-15

Terms related to this study

Keywords Provided by Researchers

  • Alzheimer's Disease
  • Synapses
  • Cognition
  • Neuroprotection
  • Neurons
  • mGluR5

Additional Relevant MeSH Terms

  • Alzheimer's Disease